

Policy code	CPG_TO_BTB_0120
Date	January, 2020
Purpose	To ensure a consistent approach to the management of beta blocker poisoning.
Scope	Applies to Queensland Ambulance Service (QAS) clinical staff.
Health care setting	Pre-hospital assessment and treatment.
Population	Applies to all ages unless stated otherwise.
Source of funding	Internal – 100%
Author	Clinical Quality & Patient Safety Unit, QAS
Review date	January, 2023
Information security	UNCLASSIFIED – Queensland Government Information Security Classification Framework.
URL	https://ambulance.qld.gov.au/clinical.html

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: <u>Clinical.Guidelines@ambulance.qld.gov.au</u>

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

 $\ensuremath{\mathbb{C}}$ State of Queensland (Queensland Ambulance Service) 2020.



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.o/deed.en

For copyright permissions beyond the scope of this license please contact: <u>Clinical.Guidelines@ambulance.qld.gov.au</u>

Beta blocker

January, 2020

Beta blockers are beta adrenergic receptor antagonists which are commonly prescribed for the management of cardiac arrhythmia, hypertension and following myocardial infarction.

Toxicity from accidental or intentional overdose is not uncommon, causing bradycardia that is associated with significant mortality.

Examples include:

- Propranolol
- Sotalol
- Atenolol
- BisoprololCarvedilol

Clinical features

Cardiovascular effects

- Bradycardia
- Heart block
- Hypotension
- Cardiogenic shock

Other effects

- Hypoglycaemia/hyperglycaemia
- Pulmonary oedema
- Seizures, coma (propranolol)

Risk assessment

- Propranolol and sotalol are particularly toxic in overdose due to their action on other channels.
 - Propranolol is a sodium channel blocker that crosses the blood-brain barrier. In overdose, in addition to its beta blocking effects, it causes seizures, coma and QRS widening due to sodium channel blockade.
 - Sotalol, in addition to its beta blocking effects, also blocks potassium channels which causes QT prolongation and can lead to Torsades de Pointes.
- Other beta blocking drugs are relatively less toxic in isolation; however, their effects can be compounded when taken as a co-ingestion with other cardiac drugs such as calcium channel blockers or digoxin, or if the patient has poor cardiac reserve (e.g. older adults or those with underlying heart disease).

WHEN PRINTED

